e-SPACE Cardio-Renal-Metabolic 2024
Published: 29 March 2024
-
Views:
211
-
Likes:
7
-
Views:
211
-
Likes:
7
-
Up Next -
1h 8m 49sPart 2 | Session 4 Plenary Session 8 – Early intervention and intensive management
-
27m 17sPart 2 | Session 5 Effects of GLP- 1RA on kidney outcomes in CKD and T2D
-
1h 3m 47sPart 2 | Session 6 Plenary Session 9 – Precision medicine in CRM
-
1h 6sPart 1 | Session 1 Plenary Session 1 – Multidisciplinary implementation strategies Gerasimos Filippatos, Manisha Sahay, Gianluigi Savarese, Francesco Cosentino, Sam Seidu
-
28m 56sPart 1 | Session 2 Keynote Session – KDIGO guideline updates 2024 Paul Stevens
-
1h 2m 27sPart 1 | Session 3 Plenary Session 2 – Guideline directed therapy for CRM disease: the evidence base Intissar Haddiya, Lars H Lund, Marco Metra, Nikolaus Marx, Peter Rossing, Giuseppe Rosano
-
59m 47sPart 1 | Session 4 Plenary Session 3 – Managing the patients with CRM: who gets what, when and why? Gianluigi Savarese, Alice Cheng, Adeera Levin, Antonio Ceriello, Shelley Zieroth, Giuseppe Rosano
-
57m 21sPart 1 | Session 5 Plenary Session 4 – Weight homeostasis management in CRM disease (Organised with support from Charité Friends & Sponsors Trust) Scott Isaacs, Peter Rossing, Muthiah Vaduganathan, Stefan Anker, Javed Butler
-
1h 7sPart 1 | Session 6 Plenary Session 5 – CRM disease: epidemiology and pathophysiology Ahmed Bennis, Ileana L Piña, Giulia Ferrannini, Chiadi Ndumele, Rodica Pop-Busui, Mitja Lainscak
-
54m 56sPart 2 | Session 1 Plenary Session 6 – Anaemia and iron deficiency John GF Cleland, Gerasimos Filippatos, Ewa Jankowska, David Wheeler, Kieran Docherty
-
16m 6sPart 2 | Session 2 Practical implementation of non-steroidal mineralocorticoid receptor antagonists to reduce cardiorenal risk Muthiah Vaduganathan, David Charytan
Overview
KDIGO and Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology were delighted to announce the return of e-SPACE Cardio-Renal-Metabolic (CRM) 2024.
A thoughtfully curated programme supported the exploration of how leading experts, in cardiology, nephrology and diabetology, treat the interrelated diseases.
This event once again brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Related sessions to e-SPACE Cardio-Renal-Metabolic 2024:
Learning Objectives
- Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality and reduced quality of life affecting individuals around the world
- Describe the complexity and interlink between the three conditions
- Discuss existing guidelines and best approaches for screening patients
- Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease and obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
- Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes
Target Audience
- Cardiologists
- Nephrologists
- Diabetologists
- General Practitioners (GPs)
- HF Specialists
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day One
Part 2
Day Two
Faculty Biographies
Michel Jadoul
Clinical Professor
Prof Michel Jadoul is a Clinical Professor at Université catholique de Louvain, Ottignies-Louvain-la-Neuve, BE.
Prof Jadoul's clinical activities include the follow-up of hemodialysis and CKD patients. His main research interests include hepatitis C, beta2m amyloidosis and other complications in hemodialysis patients, as well as CV complications after kidney TP and various causes of kidney disease (especially drugs).
He has (co)-authored over 330 scientific papers, most of them published in major nephrology journals.
Stephan Von Haehling
Professor of Cardiology and Consultant Cardiologist
Prof Stephan von Haehling is a Professor of Cardiology and Consultant Cardiologist at University Medicine Göttingen, Göttingen, DE.
His PhD was awarded by Imperial College, London, UK after he completed studies on inflammatory mechanisms of heart failure at the National Heart and Lung Institute in London.
Prof von Haehling is a Fellow of the European Society of Cardiology and of the Heart Failure Association of the ESC. His research interests include the pathophysiology and the co-morbidities of heart failure, with particular focus on muscle wasting, biomarkers, and novel treatments.
Sofia Ahmed
Nephrologist
Dr Sofia Ahmed is a Nephrologist at University of Calgary, Calgary, CA.
Rukshana Shroff
Consultant Paediatric Nephrologist
Dr Rukshana Shroff is a Consultant Paediatric Nephrologist at Great Ormond Street Hospital, London, UK.
Dr Shroff looks after children with chronic kidney disease (CKD) and those on dialysis.
Elke Schaeffner
Epidemiologist
Dr Elke Schaeffner is a Professor of Nephrology and health care research, as well as an Epidemiologist at Charité – Universitätsmedizin Berlin, Berlin, DE.
Dr Schaeffner's main interests include renal epidemiology and aging, with a particular focus on chronic kidney disease (CKD) in an aging society and biomarkers for assessing kidney function.
Comments